论文信息 - The Cost-Effectiveness of Second-Line Crizotinib in Eml4-Alk Rearranged Advanced Non-Small Cell Lung Cancer. - 字舞流文

The Cost-Effectiveness of Second-Line Crizotinib in Eml4-Alk Rearranged Advanced Non-Small Cell Lung Cancer.

M. Tsao | J. Hoch | D. Graham | S. Djalalov | J. Beca | N. Leighl | D. Graham | Ming-Sound Tsao | Natasha Leighl | Jeffrey Hoch | JC Cutz

[1] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[2] A. Karsan,et al. Canadian ALK (CALK): A pan-Canadian multicenter study to optimize and standardize ALK immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for ALK gene rearrangements. , 2013 .

[3] C. Earle,et al. Metastatic NSCLC: Treatment patterns, outcomes, and costs of newer agents. , 2012 .

[4] E. Brambilla,et al. Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5] Hyojin Kim,et al. Screening of Anaplastic Lymphoma Kinase Rearrangement by Immunohistochemistry in Non-small Cell Lung Cancer: Correlation with Fluorescence In Situ Hybridization , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6] A. Iafrate,et al. A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry , 2010, Clinical Cancer Research.

[7] M. Stafford,et al. Health state utilities for non small cell lung cancer , 2008, Health and quality of life outcomes.

[8] L. Tanoue,et al. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .